-
Mashup Score: 0
This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most patients, with encouraging activity. Longer follow-up will be needed to confirm these data.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ #MDS https://t.co/oBBRXqU9cs
-
-
Mashup Score: 4
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Isolated CD34-positive cell samples from post-transplant patients with #MDS had significantly higher variant allele frequency compared with bulk bone marrow cell samples. Read more from the study led by Carolin Lindholm of @karolinskainst. ➡️ https://t.co/wRP6yCpKLV https://t.co/I1Z5XNCHto
-
-
Mashup Score: 1Luspatercept, Improved Diagnostics Deliver in MDS - 5 day(s) ago
“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future.”
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
A shift in a greater understanding of molecular genetics has led to improved prognostic capabilities in #MDS. https://t.co/hZHfSHEqmp https://t.co/6v9oINXAvX
-
-
Mashup Score: 0
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
In the latest episode of “The HemOnc Pulse," @AfafOsman7, of @huntsmancancer, discusses how high-risk #MDS are distinct from lower-risk classifications and how to approach treatment. 🎧 Listen here! https://t.co/WGC7tsvajR https://t.co/qx8dq5PyTf
-
-
Mashup Score: 1
Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with myelodysplastic syndromes.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with myelodysplastic syndromes #MDS, Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option compared with antithymocyte globulin, as per a study. https://t.co/hFg2EGKL06
-
-
Mashup Score: 3
Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes. #MDS | @Dr_AmerZeidan @YaleCancer https://t.co/FQWKH9QXVs
-
-
Mashup Score: 5
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Out now! 🎉 An expert panel ft. Drs. Guillermo Garcia-Manero (@MDAndersonNews), Jamie Koprivnikar (@HMHNewJersey), Solly Chedid (@mySingingRiver), and @tomleblancMD (@DukeCancer) discuss the current #MDS treatment landscape. Watch here ➡️➡️ https://t.co/F6EkDSR85g https://t.co/IvHTGhIPJy
-
-
Mashup Score: 3
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes. #MDS | @KUMedCenter https://t.co/veylhAkhIj
-
-
Mashup Score: 1
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A new multivariate model developed by researchers from @MDAndersonNews enhances prognosis for HMA-treated #MDS. 📰 Read more: https://t.co/yhAMAQqexb https://t.co/IDLlCxfOYo
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study -#MDS The Lancet Haematology https://t.co/htsm7208ZT